Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a
AI-Driven Collaboration Enhances Efficiency in Drug Development The landscape of drug development is undergoing a transformative shift. Today, advanced technologies like artificial intelligence (AI) are converging with traditional laboratory practices, promising a new era of efficiency and
Johnson & Johnson (J&J) has announced plans to construct a state-of-the-art biologics plant in Wilson, North Carolina, with construction set to commence in the first half of 2025. This ambitious project comes with a substantial investment exceeding $2 billion, aimed at bolstering J&J's supply chain
Boston-based Aktis Oncology is making significant strides in the biopharmaceutical industry, standing out for its innovative efforts in developing radiopharmaceutical medicines aimed at treating cancer. The company recently secured a substantial $175 million in a Series B funding round, designed to
Ireland’s biopharma industry stands as an indispensable pillar of the nation’s economy, evidencing significant contributions and future growth potential. In 2022 alone, the sector accounted for 32% of the country's industrial exports, amassing over €42 billion, and directly employed nearly 50,000
Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has reached a significant milestone in the development of treatments for post-traumatic stress disorder (PTSD). The company recently announced a Material Transfer Agreement (MTA) with the U.S. Army Medical
The global biopharmaceutical contract manufacturing market is anticipated to experience significant growth from 2024 to 2032. This market's expansion is driven by continuous technological innovations, increased research and development (R&D) investments, and strategic collaborations among key
Biomanufacturing, the engineering of biological materials for products like pharmaceuticals, is poised for radical change. Historically reliant on specialized labor and manual processes, the sector is now at the cusp of a technological revolution powered by artificial intelligence (AI) and machine
Eli Lilly has announced substantial investments to expand its manufacturing capabilities in Ireland, with over $1 billion allocated to its Limerick facility and $800 million to its site in Kinsale. These expansions aim to significantly boost production capacities for essential biologic active
The launch of Richter BioLogics' state-of-the-art biopharmaceutical Current Good Manufacturing Practice (cGMP) facility in Bovenau, Germany marks a significant milestone for the company and the industry at large. Positioned as a forefront leader in advanced biopharmaceutical production, the new
ITCurated uses cookies to personalize your experience on our website. By continuing to use this site, you agree to our Cookie Policy